Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target

Wedbush analyst David Nierengarten has reiterated an Outperform rating on Cogent Biosciences (NASDAQ: COGT) and has maintained a price target of $55 for the company's stock.